



Attorney's Docket No. L0461/7063

11/2/01  
9/6/01  
RBB

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Van Snick et al.  
Serial No: 09/336,091  
Filed: June 18, 1999  
For: MAGE-A1 PEPTIDES PRESENTED BY HLA CLASS II MOLECULES  
Examiner: R. Schwadron  
Art Unit: 1644

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231, on the 28<sup>th</sup> day of August, 2001.

Monica E. Zombori

RECEIVED

SEP 05 2001

COMMISSIONER FOR PATENTS  
WASHINGTON, D.C. 20231

TECH CENTER 1600/2900

Sir:

AMENDMENT

This is responsive to the Office Action mailed on May 29, 2001. Please amend the above-identified application as follows:

In the Claims

Please cancel claims 1 and II.

Please amend the claims as follows:

*Sub 01*  
2.(amended) An isolated HLA class II-binding peptide consisting essentially of the amino acid sequence set forth as SEQ ID NO:7, or a functional variant thereof comprising one amino acid addition, substitution or deletion, and

0-10 amino acids added to either or both ends of the amino acid sequence set forth as SEQ ID NO:7, or the functional variant thereof.

*C2*  
5.(amended) The isolated HLA class II-binding peptide of claim 2 wherein the isolated peptide comprises an endosomal targeting signal.

*Sup 1527*